Rodel Bobadilla
Family · Columbia, SCNPI 1942312111
Payments from drug & device makers
Across 574 payments — averaging $17.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Amgen$972
- AstraZeneca$804
- Merck$668
- Pfizer$652
- E.r. Squibb & Sons, L.L.C.$632
- plus $5K from 24 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 103 | $1,729 |
| Amgen | 67 | $972 |
| AstraZeneca | 47 | $804 |
| Merck | 38 | $668 |
| Pfizer | 38 | $652 |
| E.r. Squibb & Sons, L.L.C. | 46 | $632 |
| Alnylam Pharmaceuticals Inc. | 31 | $570 |
| Johnson & Johnson | 39 | $509 |
| Boston Scientific | 22 | $456 |
| Boehringer Ingelheim | 21 | $401 |
| Philips North America LLC | 15 | $388 |
| Bayer | 23 | $368 |
| Abbott | 13 | $305 |
| Esperion Therapeutics, Inc. | 12 | $218 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $215 |
| Scpharmaceuticals Inc. | 10 | $194 |
| Lexicon Pharmaceuticals, Inc. | 8 | $150 |
| Altathera Pharmaceuticals LLC | 1 | $125 |
| Kiniksa Pharmaceuticals, Ltd. | 7 | $120 |
| Abiomed | 4 | $84 |
| Atricure, Inc. | 3 | $83 |
| Novo Nordisk | 2 | $57 |
| Actelion Pharmaceuticals US, Inc. | 3 | $55 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $46 |
| Arbor Pharmaceuticals, Inc. | 2 | $36 |
| Regeneron Healthcare Solutions, Inc. | 2 | $31 |
| Bridgebio Pharma, Inc. | 1 | $29 |
| Kestra Medical Technology Services, Inc. | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Chiesi USA, Inc. | 1 | $18 |
How this compares
$9,966 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other family in Columbia
- Mary WilliamsColumbia$67K
- Devon DriverColumbia$21K
- Amanda CharltonColumbia$15K
- Katherine ColemanColumbia$15K
- Melissa RedmondColumbia$13K
- Andrew FieldsColumbia$12K
- Jodi MyersColumbia$12K
- Alaina McClerklinColumbia$11K
- Coty CampbellColumbia$11K
- Patricia DaileyColumbia$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.